AcelRx Pharmaceuticals names new vice president of clinical operations

In this new position, Mr Evashenk will assist in defining developmental strategy, guiding clinical protocol design and study conduct, and managing risk assessment. He will report to Pamela Palmer, the company’s chief medical officer.

Mr Evashenk has over 25 years of pharmaceutical and device development experience with a focus on project management and clinical operations, most recently as director of clinical operations at Alza, a Johnson & Johnson Company.

Dr Palmer said: “We are very fortunate to continue to attract leaders in the pharmaceutical industry; Mark possesses an unparalleled breadth and depth of experience that will be of great value to AcelRx. Mark will play a vital role in overseeing all phases of clinical development, with a particular emphasis on the successful execution of studies planned for our mid- and late-stage product candidates.”